RedHill Biopharma net loss widens 48% to USD 6.1 million in first half 2026

Bitget2026/09/30 20:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

RedHill Biopharma posted a net loss of USD 6.1 million for the six months ended June 30, 2026, widening from USD 4.1 million.
Loss from continuing operations widened to USD 5.72 million from USD 2.94 million, while operating loss increased to USD 4.13 million.
Financial expenses rose to USD 1.61 million from USD 849,000, while revenue was nil versus USD 286,000.
Cash and cash equivalents totaled USD 5.16 million at June 30, 2026, and net cash used in operating activities was USD 4.56 million.
Strategic reset includes buying commercialization rights to Rebyota and Clenpiq for USD 12 million, funded by a USD 18 million Talicia divestment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN60420) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

RedHill Biopharma net loss widens 48% to USD 6.1 million in first half 2026

You may also like

Crypto prices